SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Biotech / Medicalbiocircuits BIOC


Previous 10 Next 10 
To: Craig Rodkin who wrote (54)7/23/1997 4:42:00 PM
From: Steve Robinett
   of 65
 
Craig, The sell order sounds like the right decision to me. The 144s are probably from the July financing--sell the stock, get your money back and a small profit, maybe hang onto the warrants.
Steve

Share RecommendKeepReplyMark as Last Read


To: Steve Robinett who wrote (55)8/7/1997 12:09:00 AM
From: soozathelooza
   of 65
 
looks like we had a nice
22% pop today.

with decent volume....
lets see if it holds tomorrow...

paul.

Share RecommendKeepReplyMark as Last Read


To: soozathelooza who wrote (56)8/7/1997 1:22:00 AM
From: Steve Robinett
   of 65
 
Paul, Somebody either knows something or thinks he/she knows something. I have doubts whether it's off to the races considerings the company's precarious finances. But you never know.
Best,
Steve

Share RecommendKeepReplyMark as Last Read


To: Steve Robinett who wrote (57)8/7/1997 7:49:00 PM
From: soozathelooza
   of 65
 
i agree steve...

if you look at BIOC during the last
couple of months, it has constantly taken
2 steps up and one step back.
its been looking preety solid.

i didnt put my life into BIOC
but a double at $2 is not out of the question.

(hopefully the insiders DO know something !}

goodluck...paul.

Share RecommendKeepReplyMark as Last Read


To: soozathelooza who wrote (58)8/19/1997 5:18:00 PM
From: John Liu
   of 65
 
Anyone see the news stories about BIOC's product on TV. Yesterday night I saw a news program that did a pretty lengthy discussion about their product. Anyone else?

John

Share RecommendKeepReplyMark as Last Read


To: John Liu who wrote (59)10/22/1997 2:36:00 PM
From: Epics
   of 65
 
anyone still follow this stock?

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Epics who wrote (60)11/11/1997 11:38:00 AM
From: Bob C.
   of 65
 
News release...

Is there anyone out there still interested in this stock. It seems to be making a good move toward marketing their products. Here is a news announcement out today...

SUNNYVALE, Calif., Nov. 11 /PRNewswire/ -- Biocircuits Corporation
(NASDAQ:BIOC) announced today that transfer of sales marketing
responsibilities for the IOS(R) system will occur on November 17th.
Biocircuits previously announced the signing of an agreement with Becton
Dickinson whereby Becton Dickinson acquired the exclusive worldwide sales and
marketing rights for the I0S system and all present and future cartridges.
Training of the Becton Dickinson US Point Of Care sales force will occur at
the Becton Dickinson national sales meeting on November 15th.
Under the terms of the agreement, Becton Dickinson also acquired the right
to manufacture the IOS system instrument commencing January 1, 1998.
Biocircuits will continue to manufacture all test cartridges and to develop
new cartridges, including tests for Digoxin, Free T4 and PSA. Decisions for
the selection of the next tests for development will be shared by both
companies.
The IOS system is the first easy to use and economical system for
performing immunoassays in locations such as the physician's office. Although
approximately 36,000 such sites currently have the requisite moderately
complex license for performing such tests, most send the testing out to large
laboratories since an appropriate system has not been available to do the
testing at the site. Becton Dickinson currently sells the QBC(R) hematology
system and the Affirm VP(R) system to these moderately complex licensed
facilities.
Actual results may differ from the above forward looking statement due to
a number of important factors, and will be dependent upon Becton Dickinson
successfully manufacturing the IOS instrument and marketing the existing and
proposed products, as well as the timely development and regulatory approval
of additional products. Additional risk factors are more fully discussed in
the Company's most recent reports on Forms 10-K and 10-Q and the Company's
resale Registration Statement No. 333-26079.

SOURCE Biocircuits Corporation
-0- 11/11/97
/CONTACT: John Kaiser, President & CEO, 408-752-8706, or James Welch,
Vice President & CFO, 408-752-8728, both of Biocircuits Corporation/
/Company News On-Call: prnewswire.com or fax, 800-758-5804,
ext. 113540/

Bob

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Bob C. who wrote (61)11/18/1997 12:23:00 AM
From: lizard lick
   of 65
 
Been following this one forever, still waiting, check out
the new PCIT thread,point of care technologies, this one is primed for
some real growth, started converage last week. Aol message board
starting up now to.

Share RecommendKeepReplyMark as Last ReadRead Replies (2)


To: lizard lick who wrote (62)11/19/1997 10:25:00 AM
From: Bob C.
   of 65
 
Thanks, I will take a look at PCIT. What is your current read on BIOC? Do you think it has a chance to pull itself out of this problem. The stock has gone down slightly since the marketing announcement, but the down market could be effecting it also. Their financials are not very impressive, but I understand they have a very good product. Do you think they have a chance?

Bob

Share RecommendKeepReplyMark as Last Read


To: lizard lick who wrote (62)1/11/1998 3:16:00 PM
From: PACKRATCAT
   of 65
 
Thanks Lizard, nice name. Will follow on suggested locations.

Matthew

Biocircuits Begins Clinical Evaluation for Free T4 Test Cartridge

SUNNYVALE, Calif. -- Biocircuits Corporation (Nasdaq: BIOC) announced today that clinical evaluation of a new test cartridge for use in the IOS(R) immunoassay system has begun with the anticipation of filing a 510(k) application with the Food and Drug Administration following completion of the evaluation. The cartridge undergoing evaluation determines the concentration of Free T4, a hormone produced by the Thyroid gland, and is used as an aid to diagnose thyroid disease.

"The internal and external clinical evaluation normally takes approximately 45 days," stated Mr. John Kaiser, President and CEO. He further stated that, "Filing of the 510(k) occurs within two or three weeks of completion of the evaluation and recent data indicates that the FDA is clearing in vitro diagnostic 510(k) applications in 90 to 180 days."

As is required by the recently signed exclusive worldwide marketing agreement with Becton Dickinson, selection of the next test cartridges to begin development for the IOS system will be done jointly by Becton Dickinson and Biocircuits. "Biocircuits currently plans to have two or three new tests in development at any given time and the decisions on next tests will be made following a January meeting with Becton Dickinson," stated Mr. Kaiser.

The IOS system is the first easy to use and economical system for performing immunoassays in the physician's office. Although approximately 36,000 sites currently have the requisite moderately complex license for performing such tests, most send the testing out to large laboratories since an appropriate system for performing such tests has not been available. Currently four cartridges are available for use on the system, a T4/T Uptake combination, TSH, T4/TSH combination and a Quantitative hCG cartridge. In addition to the Free T4 cartridge, a Digoxin cartridge is also in clinical evaluation and a PSA test is in late development stages.

Actual results may differ materially from the above forward looking statements due to a number of important factors, and will be dependent on Becton Dickinson successfully manufacturing the IOS instrument and marketing the existing and proposed products, as well as the timely development and regulatory approval of additional products. Additional risk factors are more fully discussed in the Company's most recent reports on Forms 1O-K and 1O-Q and the Company's resale Registration Statement No. 333-26079.

/CONTACT: John Kaiser President and CEO, 408-752-8706, or James Welch,
Vice President and CFO of Biocircuits Corporation, 408-752-8728, both of
Biocircuits Corporation/

"Copyright(c) 1998, PR Newswire"
"Provided by Dow Jones & Company, Inc."

Share RecommendKeepReplyMark as Last ReadRead Replies (1)
Previous 10 Next 10